Tetracycline
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Tetracycline: From Antibacterial Therapy to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Tetracycline is a broad-spectrum antibiotic. It is registered in South Africa as an oral tablet, but the registration record gives no indication text. The TxGNN model predicts it may be effective for punctate epithelial keratoconjunctivitis. There are 0 clinical trials and 1 publication (a 1992 case report), so this prediction rests almost entirely on the model.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA registration record (general use: systemic antibacterial) |
| Predicted New Indication | Punctate epithelial keratoconjunctivitis |
| TxGNN Prediction Score | 99.58% |
| Evidence Level | L4 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this Evidence Pack. Tetracycline is an antibacterial that inhibits the bacterial 30S ribosomal subunit. It is also reported to have anti-inflammatory and matrix metalloproteinase (MMP)-inhibiting effects on the ocular surface, which may be relevant to corneal epithelial disease.
Punctate epithelial keratoconjunctivitis is often linked to infection, especially chlamydial conjunctivitis, and tetracyclines are antichlamydial. The only supporting paper describes two patients who developed persistent punctate keratitis after oral tetracycline or doxycycline had cleared chlamydial follicular conjunctivitis. This is indirect. It shows the drug is used in the same clinical setting, not that it treats the keratitis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1424659 | 1992 | Case report | Cornea | Two patients with chlamydial follicular conjunctivitis were treated with oral tetracycline or doxycycline, and the follicles resolved. Both later developed recurrent, bilateral punctate epithelial keratitis. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| L/20.1.1/0384 | Tetracycline Hci | Tablet (oral) | Not stated in the registration record |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The high model score is not backed by direct evidence. The only publication is a case report in which keratitis persisted after tetracycline treatment, and there are no trials. The only registered product is an oral tablet, and no ophthalmic route has been assessed.
To proceed, the following is needed:
- The SAHPRA Professional Information (PI) for warnings and contraindications, which blocks the safety screen
- Mechanism of action data from DrugBank
- Route compatibility assessment, since only an oral tablet is registered and ophthalmic use is unaddressed
- Any controlled clinical data on tetracycline in this condition
Among the other predicted indications in this pack, chronic rhinosinusitis (rank 3) has the strongest support. It is rated L2 and has one completed Phase 3 trial, but all trials tested doxycycline, not tetracycline. It may merit separate evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.